About ADVAGRAF

ADVAGRAF is a medication containing the active ingredient TACROLIMUS, which is primarily used as an immunosuppressant to prevent the rejection of transplanted organs. It works by suppressing the body's immune system, reducing the risk of organ rejection in patients who have undergone kidney, liver, or heart transplants.

Key Benefits & Uses

Prevention of kidney transplant rejection
Prevention of liver transplant rejection
Prevention of heart transplant rejection

Active Ingredient & Action

TACROLIMUS, the active ingredient in ADVAGRAF, is a calcineurin inhibitor that works by binding to calcineurin and inhibiting its activity, which is essential for the activation of T-lymphocytes. By suppressing the activation of T-lymphocytes, TACROLIMUS reduces the immune system's ability to reject transplanted organs, thereby increasing the chances of a successful transplant.

Important Notes

Patients taking ADVAGRAF should be closely monitored by their healthcare provider for signs of infection, kidney dysfunction, and other potential side effects. It is essential to follow the prescribed dosage and usage instructions carefully to minimize the risk of adverse effects. Additionally, patients should not stop taking ADVAGRAF without consulting their healthcare provider, as this can increase the risk of transplant rejection.